Ocular Therapeutix (OCUL) Operating Expenses (2013 - 2026)

Ocular Therapeutix has reported Operating Expenses for 14 years, with the latest figure at $104.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 39.55% year-over-year to $104.1 million; the trailing twelve-month figure through Mar 2026 stood at $351.5 million (up 33.27% YoY), and the FY2025 full-year result was $322.0 million, up 36.71% from the prior year.
• Operating Expenses for Q1 2026 stood at $104.1 million, up from $83.0 million in the prior quarter.
• The five-year high for Operating Expenses was $104.1 million in Q1 2026, with the low at $31.0 million in Q1 2022.
• Average Operating Expenses over 5 years is $54.9 million, with a median of $46.4 million recorded in 2024.
• Year-over-year, Operating Expenses advanced 0.73% in 2022 and soared 94.14% in 2024.
• Tracing OCUL's Operating Expenses over 5 years: stood at $33.4 million in 2022, then advanced by 4.23% to $34.9 million in 2023, then jumped by 94.14% to $67.7 million in 2024, then gained by 22.69% to $83.0 million in 2025, then grew by 25.44% to $104.1 million in 2026.
• The last three Operating Expenses figures came in at $104.1 million (Q1 2026), $83.0 million (Q4 2025), and $83.2 million (Q3 2025), per Business Quant data.

Peer Comparison